+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global Clinical Trial Supply and Logistics market for pharma set to grow to $26bn by 2024” says new Visiongain report

18 April 2019

Visiongain has launched a new pharma report Clinical Trial Supply and Logistics Market Report: Clinical Trial Manufacturing, Clinical Trial Logistics and Distributions, Clinical Trial Supply Chain Management, Clinical Trial Packaging, Clinical Trial Cold Chain Logistics.

Demands for increasingly complex and expensive clinical trials have led drug developers to look to external service providers to source clinical trial materials and deliver them to investigator sites. Demand for biological and orphan drugs will be one of the factors that drive the clinical trial supply and logistics market for pharma. Rising need for cold chain logistics will increase demand for new packaging and monitoring technologies that offer lower-cost solutions, including reusable packaging and phase change materials that allow cooling for more-specific temperature ranges.

The lead analyst of the report commented "Emerging markets offer many benefits for companies looking to conduct clinical trials, including large patient population and lower trial costs. However, these also offer unique challenges in terms of clinical trial logistics. In many of these markets, the infrastructure connecting second and third tier cities is not as developed as that connecting major cities - these destinations are harder to reach, causing delays in distribution of trial materials, possible resulting in product spoilage.

Additionally, passing through or conducting trials at multiple sites within these regions results in having to comply with varying regulatory and import/export standards. Cold chain integrity also varies within these markets, with few distributors offering a complete cold chain network throughout emerging markets. However, Visiongain predicts that improvements will be made in all these areas in the coming decade, simplifying clinical trial logistics in emerging markets and further increasing their appeal as trial destinations."

Leading companies featured in the report include ADAllen Pharma, Almac Group, Amatsigroup, Biocair International Limited, Catalent, DHL, Durbin PLC, FedEx, Fisher Clinical Services, Marken. Movianto, Packaging Coordinators Inc. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Contract Research Organisations (CROs) Market Report 2022-2032

The global Contract Research Organizations (CROs) market was valued at US$57.1 billion in 2021 and is projected to grow at a CAGR of 9.95% during the forecast period 2022-2032.

12 August 2022


Visiongain Publishes Genome Editing Technologies Market Report 2022-2032

The Global Genome Editing Technologies market is estimated to be valued at US$ 4,225.48 million in 2022. The market is projected to reach a market value of US$ 18,570.41 million by 2032. We predict strong revenue growth through to 2032.

02 August 2022


Visiongain Publishes Synthetic Biology Market Report 2022-2032

The global synthetic biology market was valued at US$13.8 billion in 2021 and is projected to grow at a CAGR of 25.52% during the forecast period 2022-2032.

27 July 2022


Visiongain Publishes Biosimilar Monoclonal Antibodies Market Report 2022-2032

The global biosimilar monoclonal antibodies market was valued at US$4,087 million in 2021 and is projected to grow at a CAGR of 23.5% during the forecast period 2022-2032.

25 July 2022